Persistent Perceptual Symptoms (HPPD)

Urgent help first

Visual or other perceptual changes that keep returning, cause distress, or come with panic, confusion, or thoughts of self-harm deserve a conversation with a doctor or mental health professional. In the US, call or text 988 (Suicide & Crisis Lifeline) for a mental health crisis, or 911 for an emergency. This page is education only. It does not tell anyone to start, stop or change a medicine.

What the term means

Hallucinogen persisting perception disorder (HPPD) describes perceptual symptoms that continue or return after the effects of a psychedelic or similar drug have worn off. The symptoms can be mild and brief, or long-lasting and burdensome. [1] The National Institute on Drug Abuse (NIDA) says some psychedelic and dissociative drugs rarely cause HPPD, and that research is limited and relies mainly on self-reports of the drugs believed to have caused symptoms. [2]

This page uses these evidence labels: established, promising but limited, insufficient evidence, mixed. Evidence labels are explained in how we label evidence.

Brief flashbacks versus HPPD

The two are not the same. NIDA describes "flashbacks" as typically mild, lasting seconds or minutes, and occurring within a week of taking a substance. People with HPPD report episodes that last longer and can recur even years later, causing distress and problems in daily life. [2]

A Swiss analysis of six controlled laboratory studies followed 142 healthy volunteers who had received LSD, psilocybin or other substances. Thirteen reported reoccurring drug-like experiences. These were mostly visual, lasted seconds to minutes, and happened within a week of the last dose. Two people had distressing experiences that faded on their own, and none met the DSM-5 criteria for HPPD or reported impairment in daily life. The authors concluded that flashbacks are not a clinically relevant problem in controlled studies with healthy participants. [3]

Those findings apply to screened volunteers in supervised studies. They do not describe people who use unregulated products in uncontrolled settings, where the sources do not give reliable rates.

What is known about who develops HPPD

A 2018 review of 45 papers called HPPD rare and poorly understood. It reported that the condition is more often diagnosed in people with earlier psychological problems or substance misuse, but can arise in anyone, even after a single exposure. [4] Label: insufficient evidence on risk factors, because the underlying reports are mostly case reports and self-reports.

Proper evidence not found for a reliable population-wide rate of HPPD. We looked at NIDA, a 2018 literature review and a 2022 controlled-study analysis; none gives a general-population figure.

Related conditions

A 2026 chapter on psychedelic-associated depersonalization-derealization disorder discusses a different but overlapping picture: feeling that the self or the surroundings are unreal for months. The author argues that psychedelics may act as a trigger in vulnerable people rather than being the sole cause, and notes this view differs from the common belief that the drug caused a "never-ending trip." [5] This is one author's argued position, not a settled finding. Clinicians may therefore see persistent symptoms as either a drug effect, a psychiatric condition that surfaced around the time of use, or both.

What treatment reports show

The sources we read describe no established treatment for HPPD. A 2025 systematic review found 31 studies covering 87 people treated with different medicines, mostly case reports and small case series. Of those treated, 28% showed full recovery and 61% partial recovery within a year. The review said the evidence for medication is unclear, and that more research is needed, including randomized trials. [1] It also reported that several studies described symptoms getting worse with one antipsychotic medicine, and that a benzodiazepine did not work when LSD was the trigger. [1]

A single case report described improvement of visual symptoms after a seizure medicine was started, after antidepressants and an antipsychotic had not helped. [6] One case report cannot show that a medicine works. Label: insufficient evidence for any treatment.

No one should start, stop or change a medicine because of these reports. Treatment decisions belong with a prescriber who knows the whole picture.

Who should talk to a professional

• Anyone with perceptual changes that persist or return and cause distress.
• Anyone with a history of psychosis, mania, or panic, since other conditions can look similar. See psychosis vulnerability.
• Anyone worried about safety, driving or work because of visual changes.

What the evidence cannot say

• Whether the number of exposures, the substance, or the person's health matters most. The reports rely on memory and self-report.
• How long symptoms last for most people.
• Whether a trial participant's lower risk in controlled studies carries over to nonmedical use.

For broader context on adverse effects, see psychedelic adverse effects and contraindications and acute psychological distress.